Citations (28)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Maria Altamura. (2012) Tachykinin NK2 receptor antagonists. A patent review (2006 – 2010). Expert Opinion on Therapeutic Patents 22:1, pages 57-77.
Read now
Read now
Articles from other publishers (27)
Liang Ye, Yifei Yang, Chunmei Li, Jianzhao Zhang, Wenyan Wang, Mingxu Ma, Hengwei Xu, Wenjing Zhang, Fangxia Zou, Zhengping Hu, Hongbo Wang & Jingwei Tian. (2023) Synthesis and evaluation of piperazinotriazoles. Discovery of a potent and orally bioavailable neurokinin-3 receptor inhibitor. European Journal of Medicinal Chemistry 257, pages 115486.
Crossref
Crossref
Gaurav Doshi, Nirav Bhatia, Hemen Ved, Aditya Pandya, Duttraj Kulkarni, Janhavi Naik, Tejal Bandiwadekar, Angel Godad & Pravin Kale. (2023) Update on Oxytocin, Phosphodiesterase, Neurokinin, Glycine as a Therapeutic
Approach in the Treatment of Schizophrenia. CNS & Neurological Disorders - Drug Targets 22:7, pages 994-1007.
Crossref
Crossref
Antonio Florido, Estefanía Moreno, Enric I. Canela & Raül Andero. (2022) Nk3R blockade has sex-divergent effects on memory in mice. Biology of Sex Differences 13:1.
Crossref
Crossref
Atul Kumar, Javeed Rasool & Qazi Naveed Ahmed. 2022. Chemistry of 2-Oxoaldehydes and 2-Oxoacids. Chemistry of 2-Oxoaldehydes and 2-Oxoacids
63
171
.
A. Florido, E. R. Velasco, C. M. Soto-Faguás, A. Gomez-Gomez, L. Perez-Caballero, P. Molina, R. Nadal, O. J. Pozo, C. A. Saura & R. Andero. (2021) Sex differences in fear memory consolidation via Tac2 signaling in mice. Nature Communications 12:1.
Crossref
Crossref
Charlène Gadais, Justyna Piekielna-Ciesielska, Jolien De Neve, Charlotte Martin, Anna Janecka & Steven Ballet. (2021) Harnessing the Anti-Nociceptive Potential of NK2 and NK3 Ligands in the Design of New Multifunctional μ/δ-Opioid Agonist–Neurokinin Antagonist Peptidomimetics. Molecules 26:17, pages 5406.
Crossref
Crossref
A. Shaam Al Abed, Nathan J. Reynolds & Nathalie Dehorter. (2021) A Second Wave for the Neurokinin Tac2 Pathway in Brain Research. Biological Psychiatry 90:3, pages 156-164.
Crossref
Crossref
Irene E Sucquart, Ruchi Nagarkar, Melissa C Edwards, Valentina Rodriguez Paris, Ali Aflatounian, Michael J Bertoldo, Rebecca E Campbell, Robert B Gilchrist, Denovan P Begg, David J Handelsman, Vasantha Padmanabhan, Richard A Anderson & Kirsty A Walters. (2021) Neurokinin 3 Receptor Antagonism Ameliorates Key Metabolic Features in a Hyperandrogenic PCOS Mouse Model. Endocrinology 162:5.
Crossref
Crossref
Paul J. Marvar, Raül Andero, Rene Hurlemann, Tiffany R. Lago, Moriel Zelikowsky & Joanna Dabrowska. (2021) Limbic Neuropeptidergic Modulators of Emotion and Their Therapeutic Potential for Anxiety and Post-Traumatic Stress Disorder. The Journal of Neuroscience 41:5, pages 901-910.
Crossref
Crossref
Richard A Anderson, Jennifer Cormier, Ruth Thieroff-Ekerdt, Malcolm Boyce, Frans van den Berg, Daniel Grau, David Turnquist, Deya Corzo & Philip Graham. (2020) Pharmacodynamic Activity of the Novel Neurokinin-3 Receptor Antagonist SJX-653 in Healthy Men. The Journal of Clinical Endocrinology & Metabolism 105:12, pages e4857-e4865.
Crossref
Crossref
Wen-Qiang Cui, Wen-Wen Zhang, Teng Chen, Qian Li, Fei Xu, Qi-Liang Mao-Ying, Wen-Li Mi, Yan-Qing Wang & Yu-Xia Chu. (2020) Tacr3 in the lateral habenula differentially regulates orofacial allodynia and anxiety-like behaviors in a mouse model of trigeminal neuralgia. Acta Neuropathologica Communications 8:1.
Crossref
Crossref
Stefan Ückert, George T. Kedia, Dimitrios Tsikas, Annika Simon, Andreas Bannowsky & Markus A. Kuczyk. (2019) Emerging drugs to target lower urinary tract symptomatology (LUTS)/benign prostatic hyperplasia (BPH): focus on the prostate. World Journal of Urology 38:6, pages 1423-1435.
Crossref
Crossref
Charlène Gadais & Steven Ballet. (2020) The Neurokinins: Peptidomimetic Ligand Design and Therapeutic Applications. Current Medicinal Chemistry 27:9, pages 1515-1561.
Crossref
Crossref
Karolina Skorupskaite, Jyothis T. George, Johannes D. Veldhuis, Robert P. Millar & Richard A. Anderson. (2017) Neurokinin 3 receptor antagonism decreases gonadotropin and testosterone secretion in healthy men. Clinical Endocrinology 87:6, pages 748-756.
Crossref
Crossref
C Mary Schooling. (2017) Tachykinin neurokinin 3 receptor antagonists: a new treatment for cardiovascular disease?. The Lancet 390:10095, pages 709-711.
Crossref
Crossref
Nilli Zmora, Ten-Tsao Wong, John Stubblefield, Berta Levavi-Sivan & Yonathan Zohar. (2017) Neurokinin B regulates reproduction via inhibition of kisspeptin in a teleost, the striped bass. Journal of Endocrinology 233:2, pages 159-174.
Crossref
Crossref
Jyothis T. GeorgeRahul Kakkar, Jayne Marshall, Martin L. Scott, Richard D. Finkelman, Tony W. Ho, Johannes VeldhuisKarolina Skorupskaite, Richard A. Anderson, Stuart McIntosh & Lorraine Webber. (2016) Neurokinin B Receptor Antagonism in Women With Polycystic Ovary Syndrome: A Randomized, Placebo-Controlled Trial. The Journal of Clinical Endocrinology & Metabolism 101:11, pages 4313-4321.
Crossref
Crossref
Raül Andero, Sarah Daniel, Ji-Dong Guo, Robert C Bruner, Shivani Seth, Paul J Marvar, Donald Rainnie & Kerry J Ressler. (2016) Amygdala-Dependent Molecular Mechanisms of the Tac2 Pathway in Fear Learning. Neuropsychopharmacology 41:11, pages 2714-2722.
Crossref
Crossref
Christel A.S. Bergström, William N. Charman & Christopher J.H. Porter. (2016) Computational prediction of formulation strategies for beyond-rule-of-5 compounds. Advanced Drug Delivery Reviews 101, pages 6-21.
Crossref
Crossref
Mathias Hallberg. (2015) Neuropeptides: Metabolism to Bioactive Fragments and the Pharmacology of Their Receptors. Medicinal Research Reviews 35:3, pages 464-519.
Crossref
Crossref
Hamid R. Hoveyda, Graeme L. Fraser, Marie-Odile Roy, Guillaume Dutheuil, Frédéric Batt, Mohamed El Bousmaqui, Julien Korac, François Lenoir, Alexey Lapin, Sophie Noël & Sébastien Blanc. (2015) Discovery and Optimization of Novel Antagonists to the Human Neurokinin-3 Receptor for the Treatment of Sex-Hormone Disorders (Part I). Journal of Medicinal Chemistry 58:7, pages 3060-3082.
Crossref
Crossref
Robert E. Litman, Mark A. Smith, Dhaval G. Desai, Thomas Simpson, Dennis Sweitzer & Stephen J. Kanes. (2014) The Selective Neurokinin 3 Antagonist AZD2624 Does Not Improve Symptoms or Cognition in Schizophrenia. Journal of Clinical Psychopharmacology 34:2, pages 199-204.
Crossref
Crossref
Stephen Hanessian, Vincent Babonneau, Nicolas Boyer, Clotilde Mannoury la Cour, Mark J. Millan & Guillaume De Nanteuil. (2014) Design and synthesis of potential dual NK1/NK3 receptor antagonists. Bioorganic & Medicinal Chemistry Letters 24:2, pages 510-514.
Crossref
Crossref
Lee A DawsonRoderick A Porter. (2013) Progress in the development of neurokinin 3 modulators for the treatment of schizophrenia: molecule development and clinical progress. Future Medicinal Chemistry 5:13, pages 1525-1546.
Crossref
Crossref
Steven S. Wesolowski & Don E. Pivonka. (2013) A rapid alternative to X-ray crystallography for chiral determination: Case studies of vibrational circular dichroism (VCD) to advance drug discovery projects. Bioorganic & Medicinal Chemistry Letters 23:14, pages 4019-4025.
Crossref
Crossref
Guy Griebel & Florian Holsboer. (2012) Neuropeptide receptor ligands as drugs for psychiatric diseases: the end of the beginning?. Nature Reviews Drug Discovery 11:6, pages 462-478.
Crossref
Crossref
Guy Griebel & Sandra Beeské. (2012) Is there still a future for neurokinin 3 receptor antagonists as potential drugs for the treatment of psychiatric diseases?. Pharmacology & Therapeutics 133:1, pages 116-123.
Crossref
Crossref